CA-DEBIOPHARM
9.1.2024 15:01:34 CET | Business Wire | Press release
MedaSystems, a pioneer in software to provide access to pre-approval medicine, is pleased to announce additional funding from Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, motivated by their vision of patient centric, data-enabled clinical research and enabling patients to access novel treatments sooner. The investment adds to a growing list of prominent digital health investors in Europe and the United States, including Nina Capital and Young Sohn, a co-founder of Veeva Systems. The funding speaks to the global nature of pre-approval access and its increasing importance in the drug development process.
“We see significant synergies between MedaSystems and Debiopharm Innovation Fund. Our mutual dedication to building new approaches to pharmaceutical drug development and patient care will help bring promising pre-approval medicine to patients around the world, faster and more equitably. This funding supports our goal of making life-saving treatments more easily available to patients and physicians while advancing research and development of new therapies,” said Fiona Smythe, CEO of MedaSystems.
MedaSystems' SaaS platform facilitates the rapid processing of treatment inquiries and introduces new data capture capabilities, streamlining treatment for patients with unmet medical needs and aiding in collecting real-world data (RWD) for regulatory submissions. The platform is a vital link that ensures smooth collaboration among key partners in situations requiring pre-approval access. Physicians can swiftly manage patient requests and oversee the entire process in-app, working seamlessly with their teams and pharmacists. Pharmaceutical companies can integrate external partners like contract research organizations (CROs), guaranteeing effective communication, integrated services, and the quick shipment of treatment.
"Debiopharm Innovation Fund is committed to breaking down barriers in healthcare and promoting patient-centered solutions. Our investment in MedaSystems aligns perfectly with our dedication to innovation and the power of digital health technology in transforming patient outcomes. We believe their visionary approach to simplifying pre-approval access will play a key role in accelerating the delivery of life-saving treatments around the world. Together, we look forward to crafting a future where every patient has timely access to the most promising therapies." said Vincent Lepreux, Investment Principal at Debiopharm Innovation Fund.
About MedaSystems
MedaSystems is the leading developer of software that streamlines the handling of requests for experimental therapies from healthcare providers, supporting both Expanded Access and Post-Trial Access. MedaSystems' secure and GxP compliant application acts as a centralized environment, connecting physicians and pharmaceutical companies to facilitate global patient access to investigational therapies. By enabling the tracking and management of inquiries and data collection from these programs, MedaSystems transforms communications with clinicians into true partnerships, significantly reducing time and frustration for both parties involved.
About Debiopharm Innovation Fund
Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, provides funding and guidance for companies with an ambition to improve the patient journey and transform pharmaceutical R&D. Since 2017, Debiopharm has invested in 15 AI and digital health companies, typically leading the investment rounds. As of September 2023, Debiopharm Innovation Fund is expanding its footprint through a new Seed financing activity.
For more information, please visit www.debiopharm.com/innovation-fund/
To learn more about investment criteria visit https://www.debiopharm.com/innovation-fund/approach/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240109101056/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting styrker sit cybersikkerhedstilbud gennem samarbejde med Trillium Information Security Systems21.3.2026 02:16:00 CET | Pressemeddelelse
Andersen Consulting udbygger sine kompetencer inden for teknologi og risikostyring gennem en samarbejdsaftale med Trillium Information Security Systems (TISS), et cybersikkerhedsfirma. Med en tilstedeværelse i Canada og Pakistan leverer TISS omfattende cybersikkerhedsløsninger til organisationer inden for finans, telekommunikation og den offentlige sektor. Virksomhedens team tilbyder et bredt udvalg af ydelser, herunder sikkerhedsvurderinger, managed security operations, red team-tjenester, digital efterforskning og hændelsesrespons samt GRC-rådgivning. Med næsten to årtiers erfaring leverer TISS adaptive, efterretningsdrevne forsvarsmekanismer, der hjælper kunder med at forudse og reagere på cybertrusler, der er i konstant udvikling. "Hos TISS arbejder vi på at skabe et mere sikkert digitalt miljø ved at give organisationer mulighed for at operere sikkert og med selvtillid," udtalte Mahir Mohsin Sheikh, administrerende direktør for TISS. "Vores samarbejde med Andersen Consulting giver
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
MUSASHI JAPAN by TAIMATSU Launches “Road to Shogun” – A Journey Through Craftsmanship and Discovery20.3.2026 13:58:00 CET | Press release
Musashi Japan by TAIMATSU Co., Ltd., a contemporary Japanese knife brand rooted in the spirit of craftsmanship and cultural harmony, has announced its newest experiential campaign: “Road to Shogun.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320887471/en/ Designed as the brand’s most ambitious customer journey to date, the campaign invites visitors to explore participating Musashi Japan stores while discovering the traditions, culture and craftsmanship that inspire the brand. Inspired by the journey towards mastery, the experience encourages participants to progress through a series of ranks whilst visiting stores and unlocking rewards that celebrate elements of everyday Japanese culture. At Musashi Japan, craftsmanship is not only about the final product, but also about the path taken to achieve mastery. The Road to Shogun reflects this philosophy by guiding customers through a journey that mirrors the dedication, cu
Futur Delivers Strong Growth and Record Profit in 202520.3.2026 12:05:00 CET | Press release
In 2025, Futur added 21,000 new customers and the inflows amounted to 34 billion kronor. At the end of the year, the total savings capital was 252 billion kronor, an increase of 7% from the previous year and a new record level. "2025 was a record year for Futur. In a market characterized by sharp market fluctuations, Futur continued to invest, grow and deliver strong results. Behind this record performance is stable customer growth, strong inflows and cost discipline. Our close cooperation with over 60 partners gives customers the freedom to choose the asset management and advisory services that best suit them. The strategy of letting the customer choose is appreciated, which is reflected in us welcoming more than 21,000 new customers during the year", says Torgny Johansson, CEO of Futur. "We are optimistic about the future. Futur has great opportunities to continue growing in the coming years by developing innovative and efficient services for savings and pensions. I am proud of how a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom